Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0162-3109(96)00095-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New drugs for the treatment of hereditary angioedema.
Expert Opin Biol Ther
January 2025
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Article Synopsis
- Revolutionary drugs have emerged in the last 5 years for hereditary angioedema (HAE), leading to better symptom control and improved quality of life for patients through innovative self-administered therapies.
- This review details currently approved treatments for HAE and future therapies under development, emphasizing advancements in understanding the disease's pathophysiology.
- New long-term prophylactic treatments and oral on-demand options aim to create personalized treatment plans, potentially allowing for attack-free remission and enhanced overall patient care.
A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors.
PLoS Comput Biol
November 2024
CSL Ltd, Bio21 Institute, Melbourne, Victoria, Australia.
Background: The kallikrein-kinin system (KKS) is a complex biochemical pathway that plays a crucial role in regulating several physiological processes, including inflammation, coagulation, and blood pressure. Dysregulation of the KKS has been associated with several pathological conditions such as hereditary angioedema (HAE), hypertension, and stroke. Developing an accurate quantitative model of the KKS may provide a better understanding of its role in health and disease and facilitate the rapid and targeted development of effective therapies for KKS-related disorders.
View Article and Find Full Text PDFA single-domain antibody targeting factor XII inhibits both thrombosis and inflammation.
Nat Commun
September 2024
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- Factor XII (FXII) is crucial for activating the body's intrinsic coagulation pathway and has a previously unclear role in inflammation.
- Treating male mice with a novel antibody (Nb-Fc) that targets FXII significantly reduced arterial thrombosis without disrupting normal blood clotting.
- The study shows that inhibiting FXII can lower inflammation-related symptoms and complications during procedures like extracorporeal membrane oxygenation (ECMO), indicating its potential as a therapeutic target for thrombo-inflammatory diseases.
C-ter100 peptide derived from Vibrio vEP-45 protease acts as a pathogen-associated molecular pattern to induce inflammation and innate immunity.
PLoS Pathog
August 2024
Department of Biomedical Science, College of Natural Sciences and Public Health and Safety, Chosun University, Gwangju, Republic of Korea.
The bacterium Vibrio vulnificus causes fatal septicemia in humans. Previously, we reported that an extracellular metalloprotease, vEP-45, secreted by V. vulnificus, undergoes self-proteolysis to generate a 34 kDa protease (vEP-34) by losing its C-terminal domain to produce the C-ter100 peptide.
View Article and Find Full Text PDFPurpose: To assess the effect of antisense therapy to block kallikrein-kinin pathway in COVID-19 patients.
Material And Methods: Randomized, placebo-controlled, double blind, controlled trial enrolling hospitalized COVID-19 patients that required supplementary oxygen to sustain peripheral oxygen saturation. Key exclusion criteria included use of mechanical ventilation or vasopressors, and patients with more than 10 days since symptom onset or more than 48 h of oxygen use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!